The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
Open accessAbstract
Precision medicines exert selective pressure on tumour cells that leads to the preferential growth of resistant subpopulations, necessitating the development of next-generation therapies to treat the evolving cancer. The PIK3CA-AKT-mTOR pathway is one of the most commonly activated pathways in human cancers, which has led to the development of small-molecule inhibitors that target various nodes in the pathway. Among these agents, first-generation mTOR inhibitors (rapalogs) have caused responses in 'N-of-1' cases, and second-generation mTOR kinase inhibitors (TORKi) are currently in clinical trials. Here we sought to delineate the likely resistance mechanisms to existing mTOR inhibitors in human cell lines, as a guide for next-generation therapies. The mechanism of resistance to the TORKi was unusual in that intrinsic kinase activity of mTOR was increased, rather than a direct active-site mutation interfering with drug binding. Indeed, identical drug-resistant mutations have been also identified in drug-naive patients, suggesting that tumours with activating MTOR mutations will be intrinsically resistant to second-generation mTOR inhibitors. We report the development of a new class of mTOR inhibitors that overcomes resistance to existing first- and second-generation inhibitors. The third-generation mTOR inhibitor exploits the unique juxtaposition of two drug-binding pockets to create a bivalent interaction that allows inhibition of these resistant mutants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature reviews. Cancer · doi:10.1038/nrc839 · Cited by 6,155
Thoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., Sabatini, D. M., & Gray, N. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900301200 · Cited by 1,803
The translational landscape of mTOR signalling steers cancer initiation and metastasis
Hsieh, A. C., Liu, Y., Edlind, M. P., Ingolia, N. T., Janes, M. R., Sher, A., Shi, E. Y., Stumpf, C. R., Christensen, C., Bonham, M. J., et al. (2012) · Nature · doi:10.1038/nature10912 · Cited by 1,313
Self-citationActive-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Feldman, M. E., Apsel, B., Uotila, A., Loewith, R., Knight, Z. A., Ruggero, D., & Shokat, K. M. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000038 · Cited by 1,111
Self-citationmTOR kinase structure, mechanism and regulation
Yang, H., Rudge, D. G., Koos, J. D., Vaidialingam, B., Yang, H. J., & Pavletich, N. P. (2013) · Nature · doi:10.1038/nature12122 · Cited by 1,075
Crystal structure of the p27Kip1 cyclin-dependent-kinase inibitor bound to the cyclin A–Cdk2 complex
Russo, A. A., Jeffrey, P. D., Patten, A. K., Massagué, J., & Pavletich, N. P. (1996) · Nature · doi:10.1038/382325a0 · Cited by 899
mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs
Dowling, R. J. O., Topisirović, I., Alain, T., Bidinosti, M., Fonseca, B. D., Petroulakis, E., Wang, X., Larsson, O. S., Selvaraj, A., Liu, Y., et al. (2010) · Science · doi:10.1126/science.1187532 · Cited by 733
Control of p70 S6 kinase by kinase activity of FRAP in vivo
Brown, E. J., Beal, P. A., Keith, C. T., Chen, J., Shin, T. B., & Schreiber, S. L. (1995) · Nature · doi:10.1038/377441a0 · Cited by 705
Genome Sequencing Identifies a Basis for Everolimus Sensitivity
Iyer, G., Hanrahan, A. J., Milowsky, M. I., Al‐Ahmadie, H. A., Scott, S. N., Janakiraman, M., Pirun, M., Sander, C., Socci, N. D., Ostrovnaya, I., et al. (2012) · Science · doi:10.1126/science.1226344 · Cited by 697
Self-citation
Cited by
Sorted by citations
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749
mTOR at the nexus of nutrition, growth, ageing and disease
Liu, G. Y., & Sabatini, D. M. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0199-y · Cited by 2,737
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Panwar, V., Singh, A., Bhatt, M., Tonk, R. K., Azizov, S., Raza, A. S., Sengupta, S., Kumar, D., & Garg, M. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01608-z · Cited by 967
mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
Zou, Z., Tao, T., Li, H., & Zhu, X. M. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00396-1 · Cited by 951
Progress in tumor-associated macrophage (TAM)-targeted therapeutics
Ngambenjawong, C., Gustafson, H. H., & Pun, S. H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.010 · Cited by 858
mTOR: Role in cancer, metastasis and drug resistance
Murugan, A. K. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.003 · Cited by 483
mTORC1 and mTORC2 in cancer and the tumor microenvironment
Kim, L. C., Cook, R. S., & Chen, J. (2016) · Oncogene · doi:10.1038/onc.2016.363 · Cited by 463
mTOR substrate phosphorylation in growth control
Battaglioni, S., Benjamin, D., Wälchli, M., Maier, T., & Hall, M. N. (2022) · Cell · doi:10.1016/j.cell.2022.04.013 · Cited by 443
PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment
Zotano, Á. G., Mayer, I. A., & Arteaga, C. L. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9637-x · Cited by 428
An overview of autophagy: Mechanism, regulation and research progress
Cao, W., Li, J., Yang, K., & Cao, D. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2020.11.004 · Cited by 422
New Modalities for Challenging Targets in Drug Discovery
Valeur, E., Guéret, S. M., Adihou, H., Gopalakrishnan, R., Lemurell, M., Waldmann, H., Grossmann, T. N., & Plowright, A. T. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201611914 · Cited by 394
Signaling Pathways Involved in the Regulation of mRNA Translation
Roux, P. P., & Topisirović, I. (2018) · Molecular and Cellular Biology · doi:10.1128/mcb.00070-18 · Cited by 332
mTOR Pathways in Cancer and Autophagy
Paquette, M., El–Houjeiri, L., & Pause, A. (2018) · Cancers · doi:10.3390/cancers10010018 · Cited by 301
Pouyan, A., Ghorbanlo, M., Eslami, M., Jahanshahi, M., Ziaei, E., Salami, A., Mokhtari, K., Shahpasand, K., Farahani, N., Meybodi, T. E., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02267-0 · Cited by 338
Inhibition of mTOR induces a paused pluripotent state
Bulut-Karslioglu, A., Biechele, S., Jin, H., Macrae, T. A., Hejna, M., Gertsenstein, M., Song, J. S., & Ramalho-Santos, M. (2016) · Nature · doi:10.1038/nature20578 · Cited by 283
Metformin as an Anticancer Agent
Vancura, A., Bu, P., Bhagwat, M., Zeng, J., & Vancurova, I. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.07.006 · Cited by 274
Goul, C., Peruzzo, R., & Zoncu, R. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00641-8 · Cited by 280
The Role of mTOR Signaling as a Therapeutic Target in Cancer
Popova, N. V., & Jücker, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041743 · Cited by 273
Jhanwar-Uniyal, M., Wainwright, J. V., Mohan, A. L., Tobias, M. E., Murali, R., Gandhi, C. D., & Schmidt, M. H. (2019) · Advances in Biological Regulation · doi:10.1016/j.jbior.2019.03.003 · Cited by 268
MTOR inhibitors in cancer therapy
Xie, J., Wang, X., & Proud, C. G. (2016) · F1000Research · doi:10.12688/f1000research.9207.1 · Cited by 266
Targeting autophagy-related protein kinases for potential therapeutic purpose
Xiang, H., Zhang, J., Lin, C., Zhang, L., Liu, B., & Ouyang, L. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.10.003 · Cited by 258
Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR
Ortega, M. A., Fraile‐Μartinez, O., Asúnsolo, Á., Buján, J., García‐Honduvilla, N., & Coca, S. (2020) · Journal of Oncology · doi:10.1155/2020/9258396 · Cited by 253
Targeting mTOR and Metabolism in Cancer: Lessons and Innovations
Magaway, C., Kim, E., & Jacinto, E. (2019) · Cells · doi:10.3390/cells8121584 · Cited by 231
Davis, O. B., Shin, H. R., Lim, C.-Y., Wu, E. Y., Kukurugya, M., Maher, C. F., Perera, R. M., Ordonez, M. P., & Zoncu, R. (2021) · Developmental Cell · doi:10.1016/j.devcel.2020.11.016 · Cited by 200
Katsuno, Y., Meyer, D. S., Zhang, Z., Shokat, K. M., Akhurst, R. J., Miyazono, K., & Derynck, R. (2019) · Science Signaling · doi:10.1126/scisignal.aau8544 · Cited by 219
Self-citationConceptual Evolution of Cell Signaling
Nair, A., Chauhan, P. S., Saha, B., & Kubatzky, K. F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133292 · Cited by 238
Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer
Nunnery, S. E., & Mayer, I. A. (2020) · Drugs · doi:10.1007/s40265-020-01394-w · Cited by 225
Recent advances and limitations of mTOR inhibitors in the treatment of cancer
Ali, E. S., Mitra, K., Akter, S., Ramproshad, S., Mondal, B., Khan, I. N., Islam, M. T., Sharifi‐Rad, J., Călina, D. C., & Cho, W. C. S. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02706-8 · Cited by 228
A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles
Rebecca, V. W., Nicastri, M. C., McLaughlin, N. P., Fennelly, C., Mcafee, Q. W., Ronghe, A. M., Nofal, M., Lim, C.-Y., Witze, E. S., Chude, C. I., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0741 · Cited by 213
Research progress of mTOR inhibitors
Chen, Y., & Zhou, X. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112820 · Cited by 219
Hybrid Drugs—A Strategy for Overcoming Anticancer Drug Resistance?
Szumilak, M., Wiktorowska‐Owczarek, A., & Stańczak, A. (2021) · Molecules · doi:10.3390/molecules26092601 · Cited by 216
The Translational Regulation in mTOR Pathway
Yang, M., Lu, Y., Piao, W., & Jin, H. (2022) · Biomolecules · doi:10.3390/biom12060802 · Cited by 217
Progress with covalent small-molecule kinase inhibitors
Zhao, Z., & Bourne, P. E. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.035 · Cited by 203
A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma
Fan, Q., Aksoy, O., Wong, R. A., Ilkhanizadeh, S., Novotny, C. J., Gustafson, W. C., Truong, A. Y.-Q., Cayanan, G., Simonds, E. F., Haas-Kogan, D., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.01.014 · Cited by 180
Self-citationCovalent targeting of the vacuolar H+-ATPase activates autophagy via mTORC1 inhibition
Chung, C. Y., Shin, H. R., Berdan, C. A., Ford, B., Ward, C. C., Olzmann, J. A., Zoncu, R., & Nomura, D. K. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0308-4 · Cited by 182
PI3K/Akt/mTOR signaling pathway in cancer stem cells
Fath, M. K., Ebrahimi, M., Nourbakhsh, E., Hazara, A. Z., Mirzaei, A., Shafieyari, S., Salehi, A., Hoseinzadeh, M., Payandeh, Z., & Barati, G. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.154010 · Cited by 173
The central moTOR of metabolism
Simcox, J., & Lamming, D. W. (2022) · Developmental Cell · doi:10.1016/j.devcel.2022.02.024 · Cited by 174
Germline and somatic mutations in the MTOR gene in focal cortical dysplasia and epilepsy
Møller, R. S., Weckhuysen, S., Chipaux, M., Marsan, E., Taly, V., Bebin, E. M., Hiatt, S. M., Prokop, J. W., Bowling, K. M., Mei, D., et al. (2016) · Neurology Genetics · doi:10.1212/nxg.0000000000000118 · Cited by 152
MiT/TFE Family of Transcription Factors, Lysosomes, and Cancer
Perera, R. M., Malta, C. D., & Ballabio, A. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055835 · Cited by 162
mTORC1 pathway in DNA damage response
Ma, Y., Vassetzky, Y. S., & Dokudovskaya, S. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2018.06.011 · Cited by 157
Huang, J., Chen, L., Wu, J., Ai, D., Zhang, J., Chen, T., & Wang, L. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01070 · Cited by 159
Overview of Research into mTOR Inhibitors
Mao, B., Zhang, Q., Ma, L., Zhao, D., Zhao, P., & Yan, P. (2022) · Molecules · doi:10.3390/molecules27165295 · Cited by 155
mTOR Cross-Talk in Cancer and Potential for Combination Therapy
Conciatori, F., Ciuffreda, L., Bazzichetto, C., Falcone, I., Pilotto, S., Bria, E., Cognetti, F., & Milella, M. (2018) · Cancers · doi:10.3390/cancers10010023 · Cited by 145
Kouidhi, S., Elgaaïed, A. B., & Chouaïb, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00270 · Cited by 145
mTOR: A Cellular Regulator Interface in Health and Disease
Boutouja, F., Stiehm, C. M., & Platta, H. W. (2019) · Cells · doi:10.3390/cells8010018 · Cited by 139
Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis
Mukherjee, R., Vanaja, K. G., Boyer, J. A., Gadal, S., Solomon, H., Chandarlapaty, S., Levchenko, A., & Rosen, N. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.01.033 · Cited by 135
Self-citationCross-talk between protein synthesis, energy metabolism and autophagy in cancer
Lindqvist, L., Tandoc, K. V., Topisirović, I., & Furic, L. (2017) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.11.003 · Cited by 140
Signaling pathways and therapeutic approaches in glioblastoma multiforme (Review)
Khabibov, M., Гарифуллин, А., Boumber, Y., Khaddour, K., Fernandez, M., Khamitov, F., Халикова, Л. В., Kuznetsova, N. S., Kit, O. I., & Kharin, L. V. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5359 · Cited by 142
Homer, J. A., Xu, L. Y., Namitharan, K., Zheng, Q., Choi, E. J., Kim, B. M., Sharpless, K. B., Zuilhof, H. T., Dong, J., & Moses, J. E. (2023) · Nature Reviews Methods Primers · doi:10.1038/s43586-023-00241-y · Cited by 129
Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer
Mortazavi, M., Moosavi, F., Martini, M., Giovannetti, E., & Firuzi, O. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103749 · Cited by 129
Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer
Alves, C. L., & Ditzel, H. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054522 · Cited by 126
NF2/Merlin Inactivation and Potential Therapeutic Targets in Mesothelioma
Sato, T., & Sekido, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19040988 · Cited by 120
Eukaryotic translation initiation factors as promising targets in cancer therapy
Hao, P., Yu, J., Ward, R. J., Liu, Y., Qiao, H., An, S., & Xu, T. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00607-9 · Cited by 127
mTORC2 controls the activity of PKC and Akt by phosphorylating a conserved TOR interaction motif
Baffi, T. R., Lordén, G., Wozniak, J. M., Feichtner, A., Yeung, W., Kornev, A. P., King, C. C., Rio, J. C. D., Limaye, A. J., Bogomolovas, J., et al. (2021) · Science Signaling · doi:10.1126/scisignal.abe4509 · Cited by 116
Faes, S., Demartines, N., & Dormond, O. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/1726078 · Cited by 104
Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy
Luo, X., He, X., Zhang, X., Zhao, X., Zhang, Y., Shi, Y., & Hua, S. (2024) · MedComm · doi:10.1002/mco2.474 · Cited by 115
Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action
Durán, I., Lambea, J., Maroto, P., González-Larriba, J. L., Flores, L. E., Granados-Principal, S. M., Graupera, M., Sáez, B., Vivancos, A. P., & Casanovas, O. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0463-4 · Cited by 101
Lawrence, R. E., Cho, K. F., Rappold, R., Thrun, A., Tofaute, M. J., Kim, D. J., Moldavski, O., Hurley, J. H., & Zoncu, R. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0148-6 · Cited by 107
Brain-restricted mTOR inhibition with binary pharmacology
Zhang, Z., Fan, Q.-W., Luo, X., Lou, K., Weiss, W. A., & Shokat, K. M. (2022) · Nature · doi:10.1038/s41586-022-05213-y · Cited by 102
Self-citationPersonalized phosphoproteomics identifies functional signaling
Needham, E. J., Hingst, J. R., Parker, B. L., Morrison, K. R., Yang, G., Onslev, J., Kristensen, J. M., Højlund, K., Ling, N. X. Y., Oakhill, J. S., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-01099-9 · Cited by 94
TGF-β Promotes Metabolic Reprogramming in Lung Fibroblasts via mTORC1-dependent ATF4 Activation
O’Leary, E. M., Tian, Y., Niğdelioğlu, R., Witt, L. J., Çetin-Atalay, R., Meliton, A. Y., Woods, P. S., Kimmig, L. M., Sun, K. A., Gökalp, G. A., et al. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0143oc · Cited by 102
Transcription and Translation Inhibitors in Cancer Treatment
Laham-Karam, N., Pinto, G., Poso, A., & Kokkonen, P. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00276 · Cited by 93
Akt phosphorylates insulin receptor substrate to limit PI3K-mediated PIP3 synthesis
Kearney, A. L., Norris, D. M., Ghomlaghi, M., Wong, M. K. L., Humphrey, S. J., Carroll, L., Yang, G., Cooke, K. C., Yang, P., Geddes, T. A., et al. (2021) · eLife · doi:10.7554/elife.66942 · Cited by 94
Targeting mTOR for fighting diseases: A revisited review of mTOR inhibitors
Xu, T., Sun, D., Chen, Y., & Ouyang, L. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112391 · Cited by 97
Liu, H., Qiu, W., Sun, T., Wang, L., Du, C., Hu, Y., Liu, W., Feng, F., Yao, C., & Sun, H. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.12.019 · Cited by 95
Autophagy Modulators: Mechanistic Aspects and Drug Delivery Systems
Tavakol, S., Ashrafizadeh, M., Deng, S., Azarian, M., Abdoli, A., Motavaf, M., Poormoghadam, D., Khanbabaei, H., Afshar, E. G., Mandegary, A., et al. (2019) · Biomolecules · doi:10.3390/biom9100530 · Cited by 92
Bradbury, R. H., Callis, R. J., Carr, G. R., Chen, H., Clark, E. A., Feron, L. J. L., Glossop, S. C., Graham, M. A., Hattersley, M. M., Jones, C., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00070 · Cited by 90
DEPTOR at the Nexus of Cancer, Metabolism, and Immunity
Caron, A., Briscoe, D. M., Richard, D., & Laplante, M. (2018) · Physiological Reviews · doi:10.1152/physrev.00064.2017 · Cited by 87
Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth
Lee, B. J., Boyer, J. A., Burnett, G. L., Thottumkara, A. P., Tibrewal, N., Wilson, S. L., Hsieh, T., Marquez, A., Lorenzana, E. G., Evans, J., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00813-7 · Cited by 87
Self-citationGraham, L. S., Banda, K., Torres, A., Carver, B. S., Chen, Y., Pisano, K., Shelkey, G., Curley, T., Scher, H. I., Lotan, T. L., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0578-9 · Cited by 84
Chemical strategies to overcome resistance against targeted anticancer therapeutics
Pisa, R., & Kapoor, T. M. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0596-8 · Cited by 84
mTOR signaling networks: mechanistic insights and translational frontiers in disease therapeutics
Zhang, H., Xiao, X., Pan, Z., & Dokudovskaya, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02493-4 · Cited by 94
The Role of Exosomal microRNA in Cancer Drug Resistance
Guo, Q.-R., Wang, H., Yan, Y.-D., Liu, Y., Su, C., Chen, H., Yan, Y., Adhikari, R., Wu, Q., & Zhang, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00472 · Cited by 85
The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer
Turnham, D. J., Bullock, N., Dass, M. S., Staffurth, J. N., & Pearson, H. B. (2020) · Cells · doi:10.3390/cells9112342 · Cited by 85
Renal cell carcinoma therapy: Current and new drug candidates
Pontes, O., Oliveira-Pinto, S., Baltazar, F., & Costa, M. F. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.07.009 · Cited by 82
Drug discovery targeting the mTOR pathway
Martelli, A. M., Buontempo, F., & McCubrey, J. A. (2018) · Clinical Science · doi:10.1042/cs20171158 · Cited by 77
Novel therapeutic approaches targeting L-type amino acid transporters for cancer treatment
Hayashi, K., & Anzai, N. (2017) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v9.i1.21 · Cited by 76
mTOR co-targeting strategies for head and neck cancer therapy
Wang, Z., Valera, J. L. C., Zhao, X., Chen, Q., & Gutkind, J. S. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9688-7 · Cited by 79
Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents
Occhiuzzi, M. A., Lico, G., Ioele, G., Luca, M. D., Garofalo, A., & Grande, F. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114971 · Cited by 75
Rad, E., Murray, J. T., & Tee, A. R. (2018) · Cancers · doi:10.3390/cancers10010005 · Cited by 73
Burnett, G. L., Yang, Y. C., Aggen, J. B., Pitzen, J., Gliedt, M. K., Semko, C. M., Marquez, A., Evans, J. W., Wang, G., Won, W. S., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01658 · Cited by 72
DRESIS: the first comprehensive landscape of drug resistance information
Sun, X., Zhang, Y., Li, H., Zhou, Y., Shi, S., Chen, Z., He, X., Zhang, H., Li, F., Yin, J., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac812 · Cited by 73
Ma, X., Lv, X., & Zhang, J. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.11.049 · Cited by 71
ASD2023: towards the integrating landscapes of allosteric knowledgebase
He, J., Liu, X., Zhu, C., Zha, J., Li, Q., Zhao, M., Wei, J., Li, M., Wu, C., Wang, J., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad915 · Cited by 69
Targeting PI3K/AKT/mTOR signaling to overcome drug resistance in cancer
Tufail, M., Wan, W., Jiang, C., & Li, N. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.111055 · Cited by 78
Ahronian, L. G., & Corcoran, R. B. (2017) · Genome Medicine · doi:10.1186/s13073-017-0431-3 · Cited by 67
Teng, M., & Gray, N. S. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.06.020 · Cited by 63
CD36-mediated endocytosis of proteolysis-targeting chimeras
Wang, Z., Pan, B., Manne, R., Chen, J., Lv, D., Wang, M., Tran, P., Weldemichael, T., Yan, W., Zhou, H., et al. (2025) · Cell · doi:10.1016/j.cell.2025.03.036 · Cited by 71
Autophagy-related signaling pathways are involved in cancer (Review)
Chen, C., Gao, H., & Su, X. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10142 · Cited by 66
mTOR signaling as a molecular target for the alleviation of Alzheimer's disease pathogenesis
Rapaka, D., Bitra, V. R., Challa, S. R., & Adiukwu, P. C. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105311 · Cited by 65
The Complex Roles of Mechanistic Target of Rapamycin in Adipocytes and Beyond
Lee, P. L., Jung, S. M., & Guertin, D. A. (2017) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2017.01.004 · Cited by 66
Ghosh, J., & Kapur, R. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.02.004 · Cited by 69
Autophagy in cancer: a complex relationship
Wilde, L. R., Tanson, K., Curry, J., & Martinez‐Outschoorn, U. (2018) · Biochemical Journal · doi:10.1042/bcj20170847 · Cited by 62
The complex network of mTOR signalling in the heart
Sciarretta, S., Forte, M., Frati, G., & Sadoshima, J. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab033 · Cited by 68
Mechanisms of resistance to mTOR inhibitors
Formisano, L., Napolitano, F., Rosa, R., D’Amato, V., Servetto, A., Marciano, R., Placido, P. D., Bianco, C., & Bianco, R. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102886 · Cited by 58
mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?
Sun, S. (2020) · Frontiers of Medicine · doi:10.1007/s11684-020-0812-7 · Cited by 58
Oricchio, E., Katanayeva, N., Collier, M. D., Sungalee, S., Pasion, J. P., Béguelin, W., Battistello, E., Sanghvi, V. R., Jiang, M., Jiang, Y., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9969 · Cited by 67
Kuroshima, K., Yoshino, H., Okamura, S., Tsuruda, M., Osako, Y., Sakaguchi, T., Sugita, S., Tatarano, S., Nakagawa, M., & Enokida, H. (2020) · Cancer Science · doi:10.1111/cas.14395 · Cited by 57
Metadata
- Authors
- Rodrik-Outmezguine, V. S., Okaniwa, M., Yao, Z., Novotny, C. J., McWhirter, C., Banaji, A., Won, H., Wong, W., Berger, M., de Stanchina, E., Barratt, D. G., Cosulich, S., Klinowska, T., Rosen, N., & Shokat, K. M.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Howard Hughes Medical Institute (US)
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Rosen, Neal
- Shokat, Kevan M.
- ORCID
- Venue
- Nature
- Published
- 2016-05-18
- Volume
- 534
- Issue
- 7606
- Pages
- 272-276
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4902179
- OpenAlex
- W2407198816
- Cited by
- 479
- References
- 28
- Citations by year
- 2026: 28 · 2025: 48 · 2024: 41 · 2023: 56 · 2022: 51 · 2021: 63 · 2020: 49 · 2019: 34 · 2018: 47 · 2017: 44 · 2016: 16
- FWCI
- 24.42
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institute on Alcohol Abuse and Alcoholism (P50AA017072)
- National Cancer Institute (P01CA129243, P01CA094060, P30CA008748)
- National Institute of General Medical Sciences (T32GM064337)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- mTOR kinase, drug resistance, mTOR inhibitors, kinase domain mutations, rapalogs, cancer therapy resistance, tumor growth inhibition
- MeSH terms
- Animals, Binding Sites, Drug Resistance, Female, Humans, Mutation, Neoplasms, Signal Transduction, Protein Structure, Tertiary, Xenograft Model Antitumor Assays, Cell Line, Tumor, Protein Kinase Inhibitors, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
